Trial Profile
Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Inflammatory breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
- 31 Jan 2024 Results assessing whether the use of RUX in TN-IBC was associated with a decrease in pSTAT3 levels despite lack of clinical benefit, published in the Breast Cancer Research
- 09 Jul 2022 Planned primary completion date changed from 1 May 2022 to 1 Dec 2022.
- 21 Feb 2022 Planned primary completion date changed from 1 Feb 2022 to 1 May 2022.